PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7991813

Echo-planar imaging.

R L DeLaPaz
View original source ↗Export metadata ↓

Abstract

Echo-planar imaging is a fast magnetic resonance (MR) imaging technique that allows acquisition of single images in as little as 20 msec and performance of multiple-image studies in as little as 20 seconds. Echo-planar imaging achieves its speed by obtaining all spatial-encoding information after a single radio-frequency (RF) excitation. Conventional imaging requires multiple-RF excitations, separated by the repetition time (TR), to acquire this information. An "infinite" TR, routine lipid suppression, and sensitivity to magnetic susceptibility are other features of echo-planar imaging. Standard pulse sequences are used to obtain echo-planar images, which have diagnostic utility similar to that of conventional MR images. Echo-planar imaging is less sensitive to motion than is conventional MR imaging and allows imaging of rapidly changing physiologic processes such as blood flow and kinetic activity. Echo-planar imaging is opening new areas of MR imaging research and clinical applications.

Explore related subjects

AbdomenEcho-Planar ImagingHeadHumansMagnetic Resonance ImagingSensitivity and SpecificityJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R L DeLaPaz. 1994. Echo-planar imaging.. https://doi.org/10.1148/radiographics.14.5.7991813

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.

BACKGROUND: This report describes the preclinical pharmacological profile of the new rapamycin analog, SDZ RAD, i.e., 40-O-(2-hydroxyethyl)-rapamycin. METHODS: The pharmacological effects of SDZ RAD were assessed in a variety of in vitro and in vivo models, which included an autoimmune disease model as well as kidney and heart allotransplantation models using different rat strain combinations. RESULTS: SDZ RAD has a mode of action that is different from that of cyclosporine or FK506. In contrast to the latter, SDZ RAD inhibits growth factor-driven cell proliferation in general, as demonstrated for the in vitro cell proliferation of a lymphoid cell line and of vascular smooth muscle cells. SDZ RAD is immunosuppressive in vitro as demonstrated by the inhibition of mouse and human mixed lymphocyte reactions and the inhibition of antigen-driven proliferation of human T-cell clones. The concentrations needed to achieve 50% inhibition in all of these assays fall into the subnanomolar range. SDZ RAD is effective in the in vivo models when given by the oral route in doses ranging between 1 mg/kg/day and 5 mg/kg/day. When compared with rapamycin, the in vitro activity of SDZ RAD is generally about two to three times lower; however, when administered orally, SDZ RAD is at least as active in vivo as rapamycin. CONCLUSIONS: In conclusion, SDZ RAD is a new, orally active rapamycin-derivative that is immunosuppressive and that efficiently prevents graft rejection in rat models of allotransplantation. SDZ RAD has therefore been selected for development for use in combination with cyclosporine A to prevent acute and chronic rejection after solid organ allotransplantation.

Abdomen↗